糖尿病肾脏病患者骨质疏松的危险因素Logistic回归分析

doi:10.3969/j.issn.1006-6233.2022.09.024

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1363 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the related risk factors of osteoporosis in patients with diabetic kidney disease. Methods: 243 patients with DKD treated in the hospital between September 2018 and September 2021 were selected. According to the examination results of the X-ray bone mineral density meter, the patients were divided into the osteoporosis group (OP group, 119 cases) and the non-osteoporosis group (NOP group, 124 cases). The general data of the two groups of patients were compared, and multivariate Logistic analysis was used to analyze the related factors affecting the occurrence of OP in patients with DKD. ROC curve was plotted to analyze the diagnostic value of Klotho and FGF-23 on the occurrence of OP in patients with DKD. Results: There were statistically significant differences between the OP group and the NOP group in terms of gender, GFR, BMI, Klotho, and FGF-23 (P<0.05). Multivariate Logistic analysis showed that gender and FGF-23 were risk factors that affected the occurrence of OP in patients with DKD, and Klotho was a protective factor affecting the occurrence of OP in patients with DKD (P<0.05). ROC curve analysis results showed that when the cut-off values of Klotho and FGF-23 were 333.33ng/L and 347.46ng/L, the areas under the curves of Klotho and FGF-23 in diagnosing OP in patients with DKD were 0.700 (95% CI: 0.635~0.765), 0.659 (95% CI: 0.591~0.728), and the sensitivities and specificities were 59.7% and 71.8%, 56.3% and 72.6% respectively. Conclusion: Female and high FGF-23 levels are risk factors to promote OP in patients with DKD, and a high Klotho level is a protective factor to inhibit OP in patients with DKD. Klotho and FGF-23 have good diagnostic value on OP in patients with DKD.

Key words： Diabetic kidney disease Osteoporosis Risk factors Protective factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2022.09.024 OR http://www.hbyxzzs.cn/EN/Y2022/V28/I9/1524

[1] 孙枫,张蕊,赵郁松.前列地尔联合非诺贝特对糖尿病肾病患者尿足细胞相关蛋白和肾功能保护的影响[J].河北医学,2020,26(5):766-771.
[2] 谭晓霞,张帆.糖尿病微血管病变合并骨质疏松症的研究进展[J].国际内分泌代谢杂志,2021,41(1):48-51.
[3] 韩冬梅,毛维维,巩伟伟,等.2型糖尿病肾病患者临床分期与骨质疏松及生长因子的关系[J].医学临床研究,2020,37(9):1297-1299.
[4] Tasnim N,Dutta P,Nayeem J,et al.Osteoporosis,an inevitable circumstance of chronic kidney disease:a systematic review[J].Cureus,2021,13(10):18488-18498.
[5] 中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南[J].中华肾脏病杂志,2021,37(3):255-304.
[6] Mohsin S,Baniyas MM,AlDarmaki RS,et al.An update on therapies for the treatment of diabetes-induced osteoporosis[J].Expert Opin Biol Ther,2019,19(9):937-948.
[7] 曹宗锐,屈晓龙,屈波,等.老年男性2型糖尿病患者骨密度及骨质疏松率的比较分析[J].成都医学院学报,2019,14(1):52-55.
[8] Chao CT,Wang J,Huang JW,et al.Chronic kidney disease-related osteoporosis is associated with incident frailty among patients with diabetic kidney disease:a propensity score-matched cohort study[J].Osteoporos Int,2020,31(4):699-708.
[9] 于利平,白勇涛,罗笑婵,等.北京社区绝经后女性骨质疏松性骨折相关危险因素和防治现况[J].中华骨质疏松和骨矿盐疾病杂志,2020,13(2):110-115.
[10] 韩业红.益气养阴通络方联用氯沙坦治疗早期2型糖尿病肾病的效果[J].医学新知,2019,29(3):273-274,278.
[11] Quarles LD.Fibroblast growth factor 23 and α-Klotho co-dependent and independent functions[J].Curr Opin Nephrol Hypertens,2019,28(1):16-25.
[12] Ribeiro AL,Mendes F,Carias E,et al.FGF23-klotho axis as predictive factors of fractures in type 2 diabetics with early chronic kidney disease[J].Diabetes Complications,2020,34(1):107476-107479.